Serina Therapeutics Inc. Common Stock (SER)

About SER

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigoti…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

16

Website

serinatherapeutics.com

Fundamentals

1-day range

$2.33$2.4

Market cap

$35.24M

P/E (trailing)

—

P/E (forward)

-2.29

EPS (trailing)

$-2.00

Dividend yield

—

Beta

-0.00

Avg. volume

86.1K

Forecasts

2 analyst ratings

Serina Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SER

  Serina Therapeutics Inc. Common Stock

  $2.46

  ▼ 2.38%
  Market cap $35.24MP/E —
  $1.22$7.92
• LTRN

  Lantern Pharma Inc. Common Stock

  $2.08

  ▼ 3.70%
  Market cap $35.47MP/E —
  $1.11$4.7
• NNVC

  NanoViricides Inc. Common Stock

  $1.24

  ▼ 3.12%
  Market cap $35.56MP/E —
  $0.85$2.23
• ENLV

  Enlivex Ltd. Ordinary Shares

  $1.35

  ▼ 8.47%
  Market cap $33.33MP/E 0.02
  $1.35$27.15
• IXHL

  Incannex Healthcare Inc. Common Stock

  $3.61

  ▼ 2.17%
  Market cap $37.21MP/E —
  $2.49$20.64
• APLM

  Apollomics Inc. Class A Ordinary Shares

  $26.6

  ▲ 1.14%
  Market cap $37.33MP/E —
  $3.66$42.12
• HYPD

  Hyperion DeFi Inc. Common Stock

  $3.25

  ▼ 10.36%
  Market cap $40.47MP/E —
  $2.34$15

P/E shows — for peers not currently carrying a live signal of their own.

• Simon Farrell · July 22, 2026 · Grant

  30.5K
• Stephen K. Brannan · July 7, 2026 · Buy

  1.0K @ $2.03
• Richard Peter Marshall · June 17, 2026 · Grant

  15.3K
• Stephen K. Brannan · June 17, 2026 · Grant

  15.3K
• Jay Venkatesan · June 17, 2026 · Conversion

  96.5K @ $2.25
• Jay Venkatesan · June 17, 2026 · Grant

  15.3K
• Jay Venkatesan · June 17, 2026 · Conversion

  224.2K @ $2.25
• Gregory Bailey · June 17, 2026 · Conversion

  762.5K @ $2.25
• Gregory Bailey · June 17, 2026 · Grant

  3.33M
• Gregory Bailey · June 17, 2026 · Grant

  15.3K
• Gregory Bailey · June 17, 2026 · Conversion

  6.67M @ $2.25
• Gregory Bailey · June 17, 2026 · Conversion

  1.77M @ $2.25
• Karen J. Wilson · June 17, 2026 · Grant

  15.3K
• Karen J. Wilson · June 12, 2026 · Buy

  5.0K @ $1.77
• Karen J. Wilson · June 11, 2026 · Buy

  5.1K @ $1.75

Institutional Ownership

March 31, 2026

Total shares held

1.43M

Total value held

$2.78M

Institutional holders

22